Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is a clinical-stage biotechnology company focused on developing natural killer cell-based therapies for patients with autoimmune diseases and cancers. The company's website is www.artivabiotherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Artiva Biotherapeutics, Inc. does
In the company’s own words
Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is a clinical-stage biotechnology company focused on developing natural killer cell-based therapies for patients with autoimmune diseases and cancers. The company's website is www.artivabiotherapeutics.com.
The company's lead product candidate, AlloNK (also known as AB-101), is an allogeneic, non-genetically modified, cryopreserved NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for B-cell driven autoimmune diseases, with refractory rheumatoid arthritis designated as the lead indication. The company is also pursuing CAR-NK product candidates through collaborator-funded trials, including AB-201, a HER2-targeting CAR-NK cell product candidate, and AB-205, a CD5-directed CAR-NK cell product candidate.
Artiva was founded in 2019 as a spinout of GC Cell Corporation, a South Korean healthcare company with over two decades of cell therapy research and manufacturing experience. The strategic partnership grants Artiva exclusive worldwide rights, excluding Asia, Australia and New Zealand, to GC Cell's NK cell manufacturing technology and programs. This manufacturing-first approach provides Artiva with a mature, scalable production process established before clinical development commenced.
The company operates a 9,000 square foot, current Good Manufacturing Practices-compliant cell production center at its San Diego headquarters. Artiva has manufactured over 50 clinical batches of AlloNK and demonstrated batch-to-batch and donor-to-donor consistency. The estimated cost of goods sold for AlloNK per patient in commercial settings would be below $3,000 to $12,000, approximately an order of magnitude lower than autologous CAR-T therapies.
As of October 1, 2025, 32 patients with autoimmune disease had been treated with AlloNK plus anti-CD20 monoclonal antibody across multiple indications. AlloNK has received Fast Track designation from the FDA in refractory rheumatoid arthritis and lupus nephritis. The company's approach aims to address limitations of existing cell therapies through improved scalability, enhanced safety profile, reduced cost, and the ability to administer treatment in community outpatient settings rather than specialized clinical centers.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1817241
- SIC
- 2836
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Artiva Biotherapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Artiva Biotherapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Artiva Biotherapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Artiva Biotherapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Artiva Biotherapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”